Swiss National Bank decreased its position in Intrexon Corp (NASDAQ:XON) by 16.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 114,900 shares of the biotechnology company’s stock after selling 22,600 shares during the quarter. Swiss National Bank owned approximately 0.07% of Intrexon worth $879,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. First Trust Advisors LP raised its holdings in Intrexon by 72.6% during the 1st quarter. First Trust Advisors LP now owns 11,227,790 shares of the biotechnology company’s stock worth $59,058,000 after purchasing an additional 4,721,782 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in Intrexon by 138.9% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,704,014 shares of the biotechnology company’s stock worth $20,713,000 after acquiring an additional 1,572,077 shares in the last quarter. Nikko Asset Management Americas Inc. grew its position in Intrexon by 133.9% in the second quarter. Nikko Asset Management Americas Inc. now owns 2,704,014 shares of the biotechnology company’s stock worth $20,713,000 after acquiring an additional 1,548,194 shares in the last quarter. Janney Montgomery Scott LLC grew its position in Intrexon by 39.7% in the second quarter. Janney Montgomery Scott LLC now owns 41,615 shares of the biotechnology company’s stock worth $319,000 after acquiring an additional 11,825 shares in the last quarter. Finally, B. Riley Wealth Management Inc. purchased a new position in Intrexon in the first quarter worth about $78,000. 75.74% of the stock is currently owned by institutional investors.

Shares of XON stock traded down $0.18 during trading hours on Thursday, reaching $6.18. 8,283 shares of the company’s stock were exchanged, compared to its average volume of 2,054,197. The business’s 50 day moving average price is $6.67. The stock has a market cap of $1.05 billion, a P/E ratio of -4.49 and a beta of 2.36. The company has a current ratio of 3.55, a quick ratio of 3.20 and a debt-to-equity ratio of 0.90. Intrexon Corp has a fifty-two week low of $3.95 and a fifty-two week high of $19.94.

Intrexon (NASDAQ:XON) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05. The firm had revenue of $35.99 million during the quarter, compared to analyst estimates of $29.62 million. Intrexon had a negative net margin of 368.47% and a negative return on equity of 31.89%. Intrexon’s revenue for the quarter was down 20.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.51) earnings per share. On average, equities research analysts forecast that Intrexon Corp will post -0.9 EPS for the current fiscal year.

In related news, insider Helen Sabzevari sold 8,484 shares of the stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $7.47, for a total value of $63,375.48. Following the sale, the insider now owns 70,825 shares of the company’s stock, valued at approximately $529,062.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Thomas Bostick sold 4,359 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $7.76, for a total transaction of $33,825.84. Following the completion of the sale, the chief operating officer now directly owns 40,236 shares in the company, valued at approximately $312,231.36. The disclosure for this sale can be found here. Insiders have sold 22,672 shares of company stock worth $173,474 over the last three months. 44.00% of the stock is owned by corporate insiders.

Several research analysts recently commented on XON shares. BidaskClub lowered Intrexon from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Bank of America dropped their target price on Intrexon from $7.00 to $6.00 and set an “underperform” rating for the company in a research report on Friday, August 9th. Northland Securities restated a “hold” rating and set a $10.00 target price on shares of Intrexon in a research report on Monday, August 12th. Finally, ValuEngine upgraded Intrexon from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.00.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: What does earnings per share mean?

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NASDAQ:XON).

Institutional Ownership by Quarter for Intrexon (NASDAQ:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.